Atom Investors’s UroGen Pharma URGN Stock Holding History

Atom Investors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.72M	Sell	46,664 -98,678	-68%	-$2.67M	0.15%	203
2026 Q1	$2.61M	Sell	145,342 -89,081	-38%	-$1.79M	0.19%	188
2025 Q4	$5.49M	Sell	234,423 -57,539	-20%	-$1.25M	0.44%	57
2025 Q3	$5.82M	Sell	291,962 -25,634	-8%	-$460K	0.44%	58
2025 Q2	$4.35M	Sell	317,596 -82,964	-21%	-$796K	0.39%	63
2025 Q1	$4.43M	Buy	400,560 +254,828	+175%	+$2.72M	0.55%	49
2024 Q4	$1.55M	Buy	+145,732	New	+$1.74M	0.19%	154
2024 Q3	–	Sell	-144,780	Closed	-$2.43M	–	614
2024 Q2	$2.43M	Buy	144,780 +94,990	+191%	+$1.35M	0.24%	132
2024 Q1	$747K	Sell	49,790 -10,375	-17%	-$170K	0.09%	262
2023 Q4	$902K	Buy	60,165 +44,505	+284%	+$578K	0.16%	198
2023 Q3	$219K	Buy	+15,660	New	+$251K	0.05%	366
2019 Q3	–	Sell	-62,863	Closed	-$2.26M	–	436
2019 Q2	$2.26M	Buy	+62,863	New	+$2.32M	0.15%	174

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Atom Investors's URGN Position: Q2 2026 in Review

Atom Investors reduced its UroGen Pharma (URGN) stake by 68% in Q2 2026, selling an estimated $2.67M and leaving 46,664 shares worth $1.72M. The position accounts for 0.15% of the portfolio, ranked #203.

Atom Investors first reported a position in URGN in Q2 2019 and has held it in 12 quarters since. The position peaked at $5.82M in Q3 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Atom Investors held 46,664 shares of UroGen Pharma worth $1.72M as of Q2 2026.
Atom Investors sold 98,678 UroGen Pharma shares in Q2 2026, an estimated $2.67M.
UroGen Pharma made up 0.15% of Atom Investors's portfolio in Q2 2026, its #203 holding.
Atom Investors first reported a position in UroGen Pharma in Q2 2019 and has held it in 12 quarters since.
Atom Investors's UroGen Pharma position peaked at $5.82M in Q3 2025.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.